The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study.

@article{Heise2008ThePA,
  title={The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study.},
  author={Tim Heise and Uta Eckers and Karin Kanc and Jakob Nis Nielsen and Leszek Nosek},
  journal={Diabetes technology & therapeutics},
  year={2008},
  volume={10 6},
  pages={479-85}
}
BACKGROUND Type 2 diabetes patients on premixed insulin are commonly prescribed biphasic insulin with low prandial insulin content, such as biphasic insulin aspart (BIAsp) 30, comprising 30% insulin aspart (IAsp). The new formulations BIAsp 50 and BIAsp 70 contain 50% and 70% soluble IAsp, respectively. We compared the pharmacodynamics (PD) and pharmacokinetics (PK) of BIAsp 30, 50, and 70 and IAsp in a glucose clamp trial. METHODS In this randomized, double-blind, crossover study at a… CONTINUE READING